Neurology companies develop therapies, diagnostics and technologies that improve understanding and treatment of disorders affecting the brain, spinal cord and nervous system. The field addresses some of the most complex challenges in modern medicine.
This category includes companies working on:
Browse 114 UK neurology companies below.
Systems biology platform for brain disease drug discovery and repurposing
BRAINCURES is a computational biotechnology company applying a systems biology approach to drug discovery for brain diseases, including Alzheimer's disease, depression, epilepsy, pain and schizophrenia. Its platform maps molecular relationships between compounds, genes and diseases, drawing on its own model of the…
Single-cell omics analysis platform for precision neuroscience research
CellClar is a UK-based Community Interest Company developing an AI-assisted software platform for single-cell omics data analysis in precision medicine. Its flagship product is designed to transform complex single-cell sequencing datasets into actionable insights for researchers working on neurodegenerative diseases,…
AI drug discovery platform targeting neurological diseases
CoSyne Therapeutics is a drug discovery company applying AI and computational methods to identify and develop therapeutics for neurological diseases. The company describes its approach as polymathic AI, integrating models across biology, chemistry, and genomics to generate and prioritise drug targets. CoSyne operates…
AAV gene therapies for neurodegenerative diseases including FTD and ALS
AviadoBio is a clinical-stage gene therapy company developing AAV-based treatments for neurodegenerative diseases. Its lead programme, AVB-101, is in a Phase 1/2 trial for frontotemporal dementia caused by GRN gene mutations, delivering a functional copy of the GRN gene via intrathalamic infusion to restore…
AI-driven neuroimaging analytics for clinical trials
Queen Square Analytics is a UCL spin-out providing advanced neuroimaging data analytics for neurological clinical trials. The company applies machine learning to MRI data for patient stratification, treatment response prediction, and imaging protocol design, with a primary focus on multiple sclerosis and…
Precision calcium channel medicines for epilepsy and Parkinson's disease
Lario Therapeutics is developing first-in-class precision medicines as disease-modifying treatments for severe neurological disorders, including genetically defined epileptic encephalopathies and Parkinson's disease. The company's pipeline centres on neuronal calcium channel inhibitors, beginning with genetically…
Global biopharma focused on neurology and rare disease therapeutics
Biogen is a global biopharma company and one of the world's first biotechnology firms. The UK and Ireland headquarters in Maidenhead employs approximately 250 people across clinical operations, regulatory affairs, drug safety, and medical affairs. The company develops and commercialises therapies for neurological,…
AAV gene therapy platform and clinical pipeline for genetic disease
AskBio UK Ltd is the European headquarters of AskBio Inc., a fully integrated AAV gene therapy company and Bayer AG subsidiary. Operating from Roslin Innovation Centre, the Edinburgh site develops the company's synthetic promoter technology, data-driven gene expression control sequences that complement AskBio's Pro10…
Antibody therapies targeting severe autoimmune diseases
argenx UK Ltd is the UK commercial subsidiary of argenx SE, a global immunology company developing antibody-based therapies for severe autoimmune diseases. The company markets VYVGART (efgartigimod), the first approved FcRn blocker in the UK, indicated for generalised myasthenia gravis and chronic inflammatory…
RNAi brain shuttle platform for neurodegenerative disease drug delivery
Aerska is a biotechnology company developing RNA interference medicines to treat, delay and prevent diseases of the brain. The company's antibody oligonucleotide conjugate platform acts as a brain shuttle, enabling RNAi therapeutics to cross the blood brain barrier and reach the central nervous system through systemic…
AI-powered medical imaging software for stroke, oncology and lung disease
Brainomix is a UK software company specialising in AI-powered imaging biomarkers and Software as a Medical Device (SaMD) to support clinical decision-making in stroke, lung fibrosis, and cancer. Its platform provides clinicians with automated imaging analysis to guide treatment decisions in acute stroke care and is…
Targeting mitochondrial dysfunction in neurodegeneration
NRG Therapeutics is a clinical-stage neuroscience company developing small molecule inhibitors of the mitochondrial permeability transition pore as disease-modifying treatments for neurodegenerative disorders. Its lead candidate, NRG5051, entered Phase 1 clinical trials in January 2026 for ALS and Parkinson's disease.…
Preclinical neuroscience CRO for translational drug development research
Transpharmation is a preclinical neuroscience contract research organisation providing translational pharmacology services to pharmaceutical and biotechnology companies. The company's therapeutic expertise spans EEG, cognition, epilepsy, pain, neurodegeneration and mood disorders including treatment-resistant…
Anti-inflammatory drugs for neurodegenerative disease
Sitala Bio is a Cambridge-based biotech developing small molecule drugs that target chronic neuroinflammation in conditions such as Parkinson's and Alzheimer's disease. The company's approach focuses on blocking microglial dysfunction to restore toxin clearance in the brain. Founded by NLRP3 inflammasome expert Matt…
Specialist CNS and psychiatric clinical trial design and delivery organisation
Clerkenwell Health is a London-based specialist contract research organisation providing clinical trial design, regulatory submission, and trial delivery services for CNS, psychiatric, and psychedelic-assisted therapy research. The company operates a purpose-built clinical site network, including an NHS-embedded…
Intranasal anti-CD3 immunotherapy for neuroinflammatory diseases
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing immunomodulatory therapies for neurological and inflammatory diseases. Its lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody designed to modulate T-cell activity through nasal administration. The 48-patient…
Macrophage-targeted therapeutics for oncology, neurological and fibrotic diseases
Macomics is a University of Edinburgh spin-out developing macrophage-targeted medicines across oncology, neurodegenerative, inflammatory and fibrotic diseases. Its ENIGMAC drug discovery platform combines human macrophage and microglia models derived from induced pluripotent stem cells, gene editing and…
AI-powered EEG platform for CNS clinical trials
Cumulus Neuroscience is a digital health software company providing an integrated brain monitoring and analytics platform for neuroscience clinical trials. Its platform combines a medical-grade EEG headset with machine learning analytics to generate objective, at-home physiological and cognitive biomarker data.…
Small molecule regulators of mitochondrial transfer for age related disease
Nascent Therapeutics is a biotechnology company developing small molecule therapies that regulate mitochondrial transfer between cells. The company's discovery platform identifies compounds that promote the uptake of healthy mitochondria into damaged cells, or block cancer cells from taking mitochondria from…
AI epigenomics platform for neurodegenerative disease detection
Prima Mente is a biotechnology company developing large-scale biological foundation models to understand and detect neurodegenerative disease. The company generates proprietary multi-omic data including whole-epigenome sequencing, and trains transformer-based models on DNA methylation patterns in cell-free DNA to…